[HTML][HTML] Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia
GN Franke, J Maier, K Wildenberger, M Cross… - The Journal of Molecular …, 2020 - Elsevier
Real-time quantitative PCR (qPCR) is routinely used to detect minimal residual disease in
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
MT Bochicchio, J Petiti, P Berchialla, B Izzo… - Cancers, 2021 - mdpi.com
Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …
[HTML][HTML] Optimized digital droplet PCR for BCR-ABL
J Maier, T Lange, M Cross, K Wildenberger… - The journal of molecular …, 2019 - Elsevier
Quantitative real-time PCR methods are commonly used to monitor BCR-ABL transcript
levels in patients with chronic myelogenous leukemia. However, standard techniques …
levels in patients with chronic myelogenous leukemia. However, standard techniques …
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts
J Petiti, M Lo Iacono, M Dragani, L Pironi… - Journal of clinical …, 2020 - mdpi.com
BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS …, 2022 - journals.plos.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
[HTML][HTML] Performance evaluation of the QXDx BCR-ABL% IS droplet digital PCR assay
HJ Chung, M Hur, S Yoon, K Hwang… - Annals of laboratory …, 2020 - ncbi.nlm.nih.gov
Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …
Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
WJ Wang, CF Zheng, Z Liu, YH Tan… - European journal of …, 2018 - Wiley Online Library
Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …
Digital PCR for BCR-ABL1 quantification in CML: current applications in clinical practice
Molecular monitoring of the BCR-ABL1 transcript for patients with chronic phase chronic
myeloid leukemia (CML) has become increasingly demanding. Real-time quantitative PCR …
myeloid leukemia (CML) has become increasingly demanding. Real-time quantitative PCR …
RT-qPCR and RT-digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia
BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical
management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the …
management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the …
[HTML][HTML] Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic …
Recent studies indicate that 40% of chronic myeloid leukemia patients who achieve
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain …
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain …
相关搜索
- bcr abl1 droplet pcr
- bcr abl digital pcr
- leukemia patients digital pcr
- bcr abl1 leukemia patients
- leukemia patients multiplex droplet
- residual disease digital pcr
- pcr assays multiplex droplet
- bcr abl disease progression
- leukemia patients residual disease
- abl1 monitoring diagnostic routine
- administration fda droplet pcr
- performance characteristics droplet pcr
- clinical practice digital pcr
- bcr abl1 clinical practice
- abl1 monitoring administration fda
- abl1 monitoring performance characteristics